Nafiseh Esmaeil

Nafiseh Esmaeil

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
NLNoushin Lotfi
Noushin Lotfi
RTRodolfo Thome
Rodolfo Thome
NRNahid Rezaei
Nahid Rezaei
GZGuang-Xian Zhang
Guang-Xian Zhang
ARAbbas Rezaei
Abbas Rezaei
NENafiseh Esmaeil
Nafiseh Esmaeil
Granulocyte-macrophage colony-stimulating factor (GM-CSF) was first described as a growth factor that induces the differentiation and proliferation of myeloid progenitors in the bone marrow. GM-CSF also has an important cytokine effect in chronic inflammatory diseases by stimulating the activation and migration of myeloid cells to inflammation sites, promoting survival of target cells and stimulating the renewal of effector granulocytes and macrophages. Because of these pro-cellular effects, an imbalance in GM-CSF production/signaling may lead to harmful inflammatory conditions. In this context, GM-CSF has a pathogenic role in autoimmune diseases that are dependent on cellular immune responses such as multiple sclerosis (MS) and rheumatoid arthritis (RA). Conversely, a protective role has also been described in other autoimmune diseases where humoral responses are detrimental such as myasthenia gravis (MG), Hashimoto's thyroiditis (HT), inflammatory bowel disease (IBD), and systemic lupus erythematosus (SLE). In this review, we aimed for a comprehensive analysis of literature data on the multiple roles of GM-CSF in autoimmue diseases and possible therapeutic strategies that target GM-CSF production.

1 September 2017 in International Immunopharmacology
Verified
Journal Article
Closed access
NENafiseh Esmaeil
Nafiseh Esmaeil
SASima Balouchi Anaraki
Sima Balouchi Anaraki
MGMarjan Gharagozloo
Marjan Gharagozloo
BMBehjat Moayedi
Behjat Moayedi

1 March 2014 in Pulmonary Circulation
Verified
Journal Article
Open access
GGGabriele Grunig
Gabriele Grunig
LMLeigh Marsh
Leigh Marsh
NENafiseh Esmaeil
Nafiseh Esmaeil
KJKatelin Jackson
Katelin Jackson
TGTerry Gordon
Terry Gordon
SPSung‐Hyun Park
Sung‐Hyun Park
Particulates from air pollution are implicated in causing or exacerbating respiratory and systemic cardiovascular diseases and are thought to be among the leading causes of morbidity and mortality. However, the contribution of ambient particulate matter to diseases affecting the pulmonary circulation, the right heart, and especially pulmonary hypertension is much less documented. Our own work and that of other groups has demonstrated that prolonged exposure to antigens via the airways can cause severe pulmonary arterial remodeling. In addition, vascular changes have been well documented in a typical disease of the airways, asthma. These experimental and clinical findings link responses in the airways with responses in the lung's vasculature. It follows that particulate air pollution could cause, or exacerbate, diseases in the pulmonary circulation and associated pulmonary hypertension. This perspective details the literature for support of this concept. Data regarding the health effects of particulate matter from air pollution on the lung's vasculature, with emphasis on the lung's inflammatory responses to particulate matter deposition and pulmonary hypertension, are discussed. A deeper understanding of the health implications of exposure to ambient particulate matter will improve our knowledge of how to improve the management of lung diseases, including diseases of the pulmonary circulation. As man‐made ambient particulate air pollution is typically linked to economic growth, a better understanding of the health effects of exposure to particulate air pollution is expected to integrate the global goal of achieving healthy living for all.

31 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NLNoushin Lotfi
Noushin Lotfi
GZGuang-Xian Zhang
Guang-Xian Zhang
NENafiseh Esmaeil
Nafiseh Esmaeil
ARAbdolmohamad Rostami
Abdolmohamad Rostami
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a multipotent cytokine that prompts the proliferation of bone marrow-derived macrophages and granulocytes. In addition to its effects as a growth factor, GM-CSF plays an important role in chronic inflammatory autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. Reports have identified monocytes as the primary target of GM-CSF; however, its effect on monocyte activation has been under-estimated. Here, using flow cytometry and ELISA we show that GM-CSF induces an inflammatory profile in human monocytes, which includes an upregulated expression of HLA-DR and CD86 molecules and increased production of TNF-α and IL-1β. Conversely, blockage of endogenous GM-CSF with antibody treatment not only inhibited the inflammatory profile of these cells, but also induced an immunomodulatory one, as shown by increased IL-10 production by monocytes. Further analysis with qPCR, flow cytometry and ELISA experiments revealed that GM-CSF blockage in monocytes stimulated production of the chemokine CXCL-11, which suppressed T cell proliferation. Blockade of CXCL-11 abrogated anti-GM-CSF treatment and induced inflammatory monocytes. Our findings show that anti-GM-CSF treatment induces modulatory monocytes that act in a CXCL-11-dependent manner, a mechanism that can be used in the development of novel approaches to treat chronic inflammatory autoimmune diseases.

20 January 2013 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
BMBehjat Moayedi
Behjat Moayedi
MGMarjan Gharagozloo
Marjan Gharagozloo
NENafiseh Esmaeil
Nafiseh Esmaeil
MMMohammad Reza Maracy
Mohammad Reza Maracy
HHHamid Hoorfar
Hamid Hoorfar
MJMohsen Jalaeikar
Mohsen Jalaeikar

2 November 2017 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
HMHossein Motedayyen
Hossein Motedayyen
NENafiseh Esmaeil
Nafiseh Esmaeil
NTNader Tajik
Nader Tajik
FKFahimeh Khadem
Fahimeh Khadem
SGSomayeh Ghotloo
Somayeh Ghotloo
ARAbbas Rezaei
Abbas Rezaei
Human amniotic epithelial cells (hAECs) which are isolated from the amniotic membrane have stem cell-like properties and immunomodulatory effects. Several protocols have been proposed for isolation of hAECs, nevertheless, there is no report concerning isolation of highly viable hAECs, with desirable yield, and without significant purity reduction. In the current study, a detailed protocol with some modification of previous ones is presented in which the amendments led to isolation of hAECs with high purity, yield and viability. Moreover, isolated hAECs were subjected to immuno-phenotyping and their physiological status was assessed using a proliferation assay. The average yield of obtained hAECs using the new modified method was 190 × 106 cells with a mean viability of 87%, with less than 1% contamination with mesenchymal stem cells (MSCs). The isolated cells were > 95% positive for the epithelial cell markers. The lowest initial plating efficiency of the cells was 80%. Freshly isolated hAECs had the ability to proliferate for 5–6 passages in a standard culture medium.